Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Axitinib
Drug ID BADD_D00193
Description Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).[L6676] Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative.[A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.
Indications and Usage Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
Marketing Status Prescription
ATC Code L01EK01
DrugBank ID DB06626
KEGG ID D03218
MeSH ID D000077784
PubChem ID 6450551
TTD Drug ID D01ZRI
NDC Product Code 54893-0043; 68554-0088; 54893-0032; 65344-0033; 63539-044; 0069-0151; 0069-0145; 63539-026
Synonyms Axitinib | AG 013736 | AG013736 | AG-013736 | Inlyta
Chemical Information
Molecular Formula C22H18N4OS
CAS Registry Number 319460-85-0
SMILES CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Fatigue08.01.01.0020.067668%
Feeling abnormal08.01.09.014--Not Available
Femur fracture15.08.03.003; 12.04.01.003--Not Available
Fistula15.03.02.001--Not Available
Flank pain20.02.03.006; 08.01.08.007; 15.03.04.0030.000533%
Flatulence07.01.04.0020.002398%
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Fracture12.04.02.001; 15.08.02.0010.002398%
Fungal infection11.03.05.001--Not Available
Gait disturbance17.02.05.016; 08.01.02.0020.005595%
Gamma-glutamyltransferase increased13.03.01.011--
Gastric haemorrhage24.07.02.007; 07.12.01.001--
Gastric ulcer07.04.03.0020.000799%
Gastritis07.08.02.0010.001066%
Gastrooesophageal reflux disease07.02.02.003--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage07.12.02.001; 24.07.02.009--Not Available
Gastrointestinal pain07.01.05.005--
Gastrointestinal perforation07.04.04.0010.000208%Not Available
Generalised oedema14.05.06.007; 08.01.07.0040.000533%
Generalised tonic-clonic seizure17.12.01.002--Not Available
Gingival bleeding24.07.02.010; 07.09.07.0010.001066%Not Available
Gingival pain07.09.04.0010.000799%
Glomerular filtration rate decreased13.13.01.0090.000799%Not Available
Glossitis07.14.01.0010.001066%Not Available
Glossodynia07.14.02.0010.004263%Not Available
Goitre14.11.01.008; 05.02.01.0010.000533%Not Available
Haemarthrosis24.07.01.046; 15.01.01.004; 12.04.03.0010.000533%Not Available
Haematemesis24.07.02.011; 07.12.02.0020.001865%Not Available
Haematochezia07.12.02.003; 24.07.02.012--Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 19 Pages